Abiraterone

Type: Product

Name: Abiraterone

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Astex Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 03:30 PM

Unknown AnalystGood afternoon, everyone, and thank you so much for coming to the 2013 UBS Global Healthcare Conference. My name is Terrence Hu, and I'm very happy to be your host for this session. It is my pleasure to introduce our next presenter, Dr. ... [Published Seeking Alpha - May 20 2013]

Entities: decitabine, Drugs, Patient, Phase II

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Secondary Hormone Therapy for Castration-Resistant Prostate Cancer

1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MassachusettsThe majority of patients with systemic prostate cancer treated with androgen deprivation therapy (ADT) will develop castration-resistant ... [Published Consultant Live - May 17 2013]

Entities: nonmetastatic, Antiandrogen, Enzalutamide, hormone therapy, Abiraterone

First reported May 14 2013 - Updated May 15 2013 - 1 reports

AUA 2013 - Session Highlights: Abiraterone shows improvement in quality of life outcomes at > 2 years of follow-up

SAN DIEGO, CA USA (UroToday.com) - The emergence of several new agents that prolong survival for men with metastatic castrate resistant prostate cancer (mCRPC) has resulted in a fast-paced revolution of the advanced prostate cancer space. To read more, ... [Published UroToday - May 14 2013]

Entities: Abiraterone, Metastatic, Prostate Cancer, San Diego (California, United States)

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Exelixis Inc

Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Exelixis, Inc. (EXEL) Bank of America Merrill Lynch Health Care Conference Call May 14, 2013 11:00 AM ETMasha Chapman – Bank of America/Merrill LynchWelcome back to our -- to the Bank of America's Health Care Conference. I'm Masha Chapman and I work on ... [Published Seeking Alpha - May 14 2013]

Entities: Tumor, Exelixis Inc, Patient, Phase II

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

The arrival of several new agents—cabazitaxel, abiraterone acetate, enzalutamide, and radium-223—is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also ... [Published The Oncologist - May 14 2013]

Entities: Metastatic, Castrate-Resistant, Cabazitaxel, Radium-223, Enzalutamide

First reported May 11 2013 - Updated May 11 2013 - 1 reports

Four new drugs on the market: Abiraterone, belatacept, vandetanib and fidaxomycine - Abstract

Among the 35 new molecular entities approved by the FDA in 2011, 17 were particularly notable for their significant contributions to the health of patients, including abiraterone acetate, vandetanib, belatacept and fidaxomicin.Tags:Disease TopicsTopics ... [Published UroToday - May 11 2013]

Entities: Belatacept, Vandetanib, Abiraterone

First reported May 08 2013 - Updated May 08 2013 - 1 reports

AUA Releases New Guidelines for Treating Castration-Resistant Prostate Cancer

Clinicians may offer treatment with abiraterone plus prednisone to patients with symptomatic mCRPC with poor performance status and no prior docetaxel chemotherapy.Clinicians may offer treatment with ketoconazole plus steroid or radionuclide therapy to ... [Published Oncology Business Review - May 08 2013]

Entities: docetaxel, Castrate-Resistant, Chemotherapy

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Prostate Cancer: No Cost-Effective Way to Save Lives

All of the current treatment strategies for castration-resistant prostate cancer (CRPC) exceed the generally accepted criteria for cost-effectiveness, according to an analysis reported here.The least costly of the regimens exceeded the $100,000 threshold ... [Published Surgical Products - May 07 2013]

Entities: Prostate Cancer, leuprolide, Cabazitaxel, Denosumab

First reported May 06 2013 - Updated May 06 2013 - 2 reports

AUA Offers Evidence-Based Guide For Sequencing CRPC Therapies

Michael Cookson, MDPatients with castration-resistant prostate cancer (CRPC) should receive treatment supported by the best evidence for specific disease characteristics, according to a clinical guideline developed by the American Urological Association ... [Published OncLive - May 06 2013]

Entities: docetaxel, Patient, Abiraterone

First reported May 05 2013 - Updated May 05 2013 - 1 reports

POLL: Pressure mounts for life-saving drug

Anti-cancer drug Zytiga is costing some men suffering prostate cancer $47,000 a year.The fight to make a life-saving drug affordable for men battling advanced prostate cancer has gone global with a groundswell of patients and doctors calling for the medicine ... [Published Maitland Mercury - May 05 2013]

Entities: Pharmaceutical Benefits Scheme, Zytiga, Drugs, Prostate Cancer, Prostate Cancer Foundation

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Doctor urges women to ‘run for your men’

Dr Naomi SharmaOXFORD cancer scientist Dr Naomi Sharma is urging women to sign up to this year’s Race for Life – and help find a cure for the UK’s biggest killer of husbands, brothers and grandfathers.Dr Sharma, 33, is conducting ground-breaking research ... [Published This is Oxfordshire - May 03 2013]

Entities: Prostate Cancer, Cancer, Abiraterone, United Kingdom

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Abiraterone acetate withdrawal syndrome: Does it exist? - Abstract

In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy.Tags:Disease TopicsTopics on Urology Health, Urinary Leakage, Treating Prostate Cancer, Prostate ... [Published UroToday - May 02 2013]

Entities: Abiraterone, Prostate Cancer, Urology

Quotes

...apabilities, Janssen expects to continue to make significant contributions to global human health and deliver strong business results," Duato said. "Our number one priority is to build upon our strong momentum with the goal of transforming patients' lives well into the future."

J&J pharma segment poised with over 10 potential new product filings by 2017 [Published Center Watch - 3 hours ago]

"In order to beat your enemy you've got to understand it. We are getting closer and closer to understanding the enemy which is cancer" Hussain adds

Clinical trial tests targeting prostate cancer treatment [Published PR Newswire - May 23 2013]

"We've spent the past five years transforming our business, and the growth we're seeing today is the direct impact of that effort" said Joaquin Duato, Worldwide Chairman, Pharmaceuticals Group. "The innovative new therapies in our pipeline will drive our next wave of growth...

J&J's Janssen Poised to Continue Driving Growth, Outlines 10+ Potential New Product Filings by 2017 [Published Benzinga.com - May 23 2013]

...of cancer treatment resistance in a variety of cancers," said Scott Cormack, President and Chief Executive Officer, OncoGenex Pharmaceuticals Inc. "With three Phase 3 trials for custirsen ongoing and multiple Phase 2 trials for OGX-427 underway, our development programs have never been stronger."

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting [Published Morningstar.com - May 22 2013]

More Content

sort by: Date \| Relevance
J&J pharma segment poised with over 10 potentia... [Published Center Watch - 3 hours ago]
Clinical trial tests targeting prostate cancer ... [Published PR Newswire - May 23 2013]
J&J's Janssen Poised to Continue Driving Growth... [Published Benzinga.com - May 23 2013]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published PR Newswire - May 23 2013]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published FinanzNachrichten.de - May 23 2013]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published Street Insider - May 23 2013]
Luke Johnson: The madness of investing in boomi... [Published Management Today Magazine - May 22 2013]
OncoGenex Announces Multiple 'Trials in Progres... [Published Morningstar.com - May 22 2013]
Exelixis CEO Presents at UBS Global Healthcare ... [Published Seeking Alpha - May 21 2013]
Astex Pharmaceuticals, Inc. Presents at UBS Glo... [Published Seeking Alpha - May 20 2013]
BTG plc: Final Results [Published Noodls - May 20 2013]
Consensus Outlook: Prostate Cancer- Competition... [Published PipelineReview - May 20 2013]
KOL Insight: Prostate Cancer: Competition inten... [Published PipelineReview - May 20 2013]
Secondary Hormone Therapy for Castration-Resist... [Published Consultant Live - May 17 2013]
FDA clears Bayer/ Algeta's prostate cancer radi... [Published PMLive - May 16 2013]
Tokai Pharmaceuticals Inks $35.5m Series E [Published PE Hub News - May 15 2013]
Tokai Pharmaceuticals Announces $35.5 Million S... [Published BioPortfolio - May 15 2013]
Exelixis' CEO Presents at Bank of America Merri... [Published Seeking Alpha - May 14 2013]
Betmiga, Lucentis and Elvanse accepted by SMC [Published PJ Online - May 14 2013]
Perspectives on Treatment of Metastatic Castrat... [Published The Oncologist - May 14 2013]
AUA 2013 - Session Highlights: Abiraterone show... [Published UroToday - May 14 2013]
Part 1: Will Array BioPharma Become A Late-Stag... [Published Seeking Alpha - May 12 2013]
Four new drugs on the market: Abiraterone, bela... [Published UroToday - May 11 2013]
Dendreon (DNDN) Q1/13 Results, Pricing the ther... [Published Proactive Investors USA - May 10 2013]
Oncothyreon Inc. (ONTY) Reports First Quarter 2... [Published BioSpace - May 10 2013]
Dendreon Narrows 1Q Loss Zacks [Published Yahoo! Finance - May 10 2013]
Is Dendreon Done After Q1 Train Wreck? [Published Seeking Alpha - May 10 2013]
Oncothyreon Inc Management Discusses Q1 2013 Re... [Published Seeking Alpha - May 09 2013]
Oncothyreon Reports First Quarter 2013 Financia... [Published Yahoo! Finance - May 09 2013]
Oncothyreon Reports First Quarter 2013 Financia... [Published Individual.com - May 09 2013]

sort by: Date \| Relevance
Deals Of The Week: Exit From Ambit Tie-Up Just ... [Published The IN VIVO Blog - Mar 15 2013] Despite ambitions to become the “global category leader in oncology,” Astellas Pharma has decided to pull the plug on a promising collaboration in acute myeloid leukemia with privately held Ambit Biosciences, potentially throwing a wrench into the ...
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Jan 25 2013]
Johnson & Johnson Issues Weak Earnings Guidance... [Published Clusterstock - Jan 22 2013] Johnson & Johnson just reported earnings for the fourth quarter of 2012. The market is focused on the weak earnings guidance the company issued for 2013, in the range of $5.35-5.45 per share, below analysts' estimates of $5.49. Revenues in Q4 were ...
Janssen-Cilag wins extended license to Zytiga i... [Published PBR - News - Jan 14 2013] The European Commission (EC) has approved broader indication of Janssen-Cilag International's oral, once-daily medication Zytiga (abiraterone acetate). ...